BMJ publications, with linked analysis and editorials published.

Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348. DO10.1136/bmj.g2547. UL http://www.bmj.com/content/348/bmj.g2547

Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348. DO  10.1136/bmj.g2545.  http://www.bmj.com/content/348/bmj.g2545

Linked analysis and editorials:

• Abbasi K. The missing data that cost $20bn. BMJ 2014; 348. DO 10.1136/bmj.g2695.  http://www.bmj.com/content/348/bmj.g2695
• Loder E, Tovey D, Godlee F. The Tamiflu trials. BMJ 2014; 348. DO 10.1136/bmj.g2630 http://www.bmj.com/content/348/bmj.g2630
• Jefferson T, Doshi P. Multisystem failure: the story of antiinfluenza drugs. BMJ 2014;348. DOi 10.1136/bmj.g2263. http://www.bmj.com/content/348/bmj.g2263
• Krumholz HM. Neuraminidase inhibitors for influenza. BMJ 2014; 348. DO 10.1136/bmj.g2548.  http://www.bmj.com/content/348/bmj.g2548
• Freemantle N, Shallcross LJ, Kyte D, Rader T, Calvert MJ. Oseltamivir: the real world data. BMJ 2014; 348. DO 10.1136/bmj.g2371.
• Jack A. Tamiflu: “a nice little earner”. BMJ 2014; 348. DO 10.1136/bmj.g2524. http://www.bmj.com/content/348/bmj.g2524